Evolus, Inc.

NasdaqGM EOLS

Evolus, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024

Evolus, Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Evolus, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -2.66 M, a -37.10% change year over year.
Evolus, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -1.94 M.
Evolus, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -3.98 M, a -15.87% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGM: EOLS

Evolus, Inc.

CEO	Mr. David Moatazedi
IPO Date	Feb. 8, 2018
Location	United States
Headquarters	520 Newport Center Drive
Employees	322
Sector	Consumer Discretionary
Industries Cosmetics Biotechnology Pharmaceuticals

Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Key trends

Past 5 years